Appointments, Successful Clinical Trials, Mergers, and New Contracts Boost Growth - Research Report on BioMarin, ARIAD, Bard, Rockwell Medical, and Health Net PR Newswire NEW YORK, September 9, 2013 NEW YORK, September 9, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Investors' Reports announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), C.R. Bard, Inc. (NYSE: BCR), Rockwell Medical Inc. (NASDAQ: RMTI), and Health Net Inc. (NYSE: HNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. BioMarin Pharmaceutical Inc. Research Report On September 3, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that Richard Ranieri has been appointed as Senior Vice President, Human Resources and Corporate Affairs, with effect from September 4, 2013. According to the Company, prior to joining BioMarin Mr. Ranieri served as the Executive Vice President, Human Resources at Dendreon Corporation from 2010 to 2013, where he was responsible for the HR function and oversaw the expansion of the workforce from 150 to 2000 employees. Jean-Jacques Bienaimé, CEO of BioMarin, said, "We are very pleased to welcome Rich to BioMarin. He brings a wealth of human resources experience to the company as we continue our rapid growth. He has the depth and breadth of global experience that BioMarin needs as it scales its operations to meet its expanding business." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-04/BMRN] -- ARIAD Pharmaceuticals, Inc. Research Report On September 4, 2013, ARIAD Pharmaceuticals, Inc. (ARIAD) announced that it has achieved enrollment of 50% of the patients planned for ARIAD's randomized Phase 3 trial of Iclusig (ponatinib) in adult patients with newly diagnosed chronic myeloid leukemia (CML). According to the Company, the said trial, which was earlier known as EPIC, aimed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-naïve CML patients. ARIAD stated that an interim analysis of efficacy, mainly with a primary endpoint of major molecular response rate (MMR) of twelve months, will be performed in Q3 2014 based on the patients enrolled to date. The Company anticipates reaching its target of enrolling 500 patients in the trial by the end of 2013. The Full Research Report on ARIAD Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-04/ARIA] -- C.R. Bard, Inc. Research Report On September 4, 2013, C.R. Bard, Inc. (Bard) announced that the Company has entered into a definitive agreement to acquire Rochester Medical Inc. (Rochester Medical) - a developer and supplier of silicone urinary incontinence and urine drainage products, for a price of $20 per share or c.$262 million in the aggregate to be paid at closing, which Bard expects later in 2013. According to Bard, this acquisition will enhance its position in the $930 million global urology homecare market. Timothy M. Ring, Bard's chairman and CEO, commented, "Rochester's double-digit growth product portfolio, including their customer access programs, is a key building block in our strategy to access faster growing markets over the long-term. We believe that strengthening our position in the home care market, and specifically the large and fast-growing intermittent self-catheter segment, is strategically important at this time." Bard informed that the transaction, structured as a merger, has been approved by the Board of Directors of both the Companies, and is subject to customary closing conditions, including the approval of the shareholders of Rochester Medical and regulatory approvals. The Full Research Report on C.R. Bard, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-04/BCR] -- Rockwell Medical Inc. Research Report On September 4, 2013, Rockwell Medical Inc. (Rockwell Medical) announced successful top-line results from the long-term CRUISE-2 Phase 3 efficacy study of SFP, a late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Rockwell Medical stated that SFP met the primary endpoint, demonstrating a statistically significant mean change in hemoglobin from baseline to End-of-Treatment. Further, Rockwell revealed that SFP met key secondary endpoints, including maintenance of hemoglobin, maintenance of reticulocyte hemoglobin, and increase in serum iron pre-to-post treatment without an increase in ferritin. This study is the second and final study of two identical Phase 3 efficacy studies to provide the clinical data to allow Rockwell Medical to file a New Drug Application (NDA) with the US FDA. The Full Research Report on Rockwell Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-04/RMTI] -- Health Net Inc. Research Report On September 4, 2013, Health Net Federal Services, LLC, (Health Net Federal Services), a wholly owned subsidiary of Health Net Inc. (Health Net), announced that the Department of Veterans Affairs (VA) has awarded a contract to the Company under its new Patient Centered Community Care program. The Company informed that with this contract, eligible Veterans will be able to receive coordinated, timely access to care through a comprehensive network of non-VA providers who meet VA quality standards when a local VA Medical Center cannot readily provide the care. According to Health Net Federal Services, it will support VA in caring veterans of the three (out of six) Patient Centered Community Care Regions namely: 1, 2, and 4, which cover all or portions of 37 states, Puerto Rico, and the Virgin Islands. The Full Research Report on Health Net Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-04/HNT] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. InvestorsReports.com SOURCE Investors' Reports Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)
Appointments, Successful Clinical Trials, Mergers, and New Contracts Boost Growth - Research Report on BioMarin, ARIAD, Bard,
Press spacebar to pause and continue. Press esc to stop.